TITLE

Identification of a strong and specific antichlamydial N-acylhydrazone

AUTHOR(S)
Zhang, Huirong; Kunadia, Anuj; Lin, Yingfu; Fondell, Joseph D.; Seidel, Daniel; Fan, Huizhou
PUB. DATE
October 2017
SOURCE
PLoS ONE;10/03/2017, Vol. 12 Issue 10, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Sexually transmitted Chlamydia trachomatis is an extremely common infection and often leads to serious complications including infertility and pelvic inflammatory syndrome. Several broad-spectrum antibiotics are currently used to treat C. trachomatis. Although effective, they also kill beneficial vaginal lactobacilli. Two N-acylhydrazones, CF0001 and CF0002, have been shown previously to inhibit chlamydial growth without toxicity to human cells and Lactobacillus spp. Of particular significance, the rate of random mutation leading to resistance of these inhibitors appears to be extremely low. Here, we report three analogs of CF0001 and CF0002 with significantly stronger inhibitory effects on chlamydiae. Even though the new compounds (termed SF1, SF2 and SF3) displayed slightly decreased inhibition efficiencies for a rare Chlamydia variant selected for CF0001 resistance (Chlamydia muridarum MCR), they completely overcame the resistance when used at concentrations of 75–100 μM. Importantly, SF1, SF2 and SF3 did not shown any toxic effect on lactobacilli, whereas SF3 was also well tolerated by human host cells. An effort to isolate SF3-resistant variants was unsuccessful. By comparison, variants resistant to rifampin or spectinomycin were obtained from smaller numbers of chlamydiae. Our findings suggest that SF3 utilizes an antichlamydial mechanism similar to that of CF0001 and CF0002, and will be more difficult for chlamydiae to develop resistance to, potentially making it a more effective antichlamydial agent.
ACCESSION #
125495735

 

Related Articles

  • Quinolones in Sexually Transmitted Diseases: State of the Art. Ridgway, G.L. // Drugs;Dec1999 Supplement 2, Vol. 58 Issue 6, p92 

    Progress in the development of fluoroquinolones for the treatment of sexually transmitted diseases has been slow. New compounds have appeared with good in vitro activity against the gonococcus, Chlamydia trachomatis and the genital mycoplasmas. However, there have been increasing reports of...

  • Eficacia clínica de fluconazol, tinidazol y clindamicina vs fluconazol, tinidazol y azitromicina en el tratamiento de infecciones cérvico-vaginales mixtas, incluidas las causadas por Mycoplasma y Chlamydia trachomatis. Villagrana-Zesati, Jesús Roberto; Guerra-Infante, Fernando M.; Sosa-González, Irma Elena // Ginecologia y Obstetricia de Mexico;May2013, Vol. 81 Issue 5, p231 

    Background: In the United States 19 million people acquire a sexually transmitted disease every year. Sexually transmitted diseases impact in gynecological terms because they may cause sterility, infertility and ectopic pregnancy. Objective: To compare the effectiveness of two combinations of...

  • News & Highlights.  // Mucosal Immunology (1933-0219);Jul2009, Vol. 2 Issue 4, p278 

    The author focuses on genital Chlamydia trachomatis infections and the potential treatment for them. He stresses that Chlamydia trachomatis infections are the most common bacterial sexually transmitted diseases worldwide, therefore vaccine research is required for their treatment. He considers...

  • Ocular Immune Responses, Chlamydia trachomatis Infection and Clinical Signs of Trachoma Before and After Azithromycin Mass Drug Administration in a Treatment Naïve Trachoma-Endemic Tanzanian Community. Ramadhani, Athumani M.; Derrick, Tamsyn; Macleod, David; Massae, Patrick; Malisa, Aiweda; Mbuya, Kelvin; Mtuy, Tara; Makupa, William; Roberts, Chrissy H.; Bailey, Robin L.; Mabey, David C. W.; Holland, Martin J.; Burton, Matthew J. // PLoS Neglected Tropical Diseases;7/16/2019, Vol. 13 Issue 7, p1 

    Background: Trachoma, caused by Chlamydia trachomatis, remains the leading infectious cause of blindness worldwide. Persistence and progression of the resulting clinical disease appears to be an immunologically mediated process. Azithromycin, which is distributed at the community level for...

  • An audit of the interval to treatment of anogenital Chlamydia trachomatis at Scottish genitourinary medicine clinics. Steedman, N.; Oroz, C.; Fernando, I.; Baguley, S. // International Journal of STD & AIDS;Feb2008, Vol. 19 Issue 2, p121 

    Timely treatment of sexually transmitted infections can reduce complications and prevent onward transmission. Several audit standards exist in this area. We audited the timeliness of treatment of 538 episodes of chlamydia at 12 Scottish genitourinary medicine clinics against a national standard...

  • The prevalence of Chiamydia trachomatis in patients who remained symptomatic after completion of sexually transmitted infection, treatment. Afrakhteh, Maryam; Mahdavi, Atossa; Beyhaghi, Hadi; Moradi, Afshin; Guy, Sima; Zafargandi, Shirin; Zonoubi, Zahra // Iranian Journal of Reproductive Medicine;Apr2013, Vol. 11 Issue 4, p285 

    Background: Sexually transmitted infections (STIs) are among the most common causes of illness in the world and have far-reaching health, economic and social consequences for many countries. Failure to diagnose and treat STIs at an early stage may result in serious complications and sequels....

  • Following up on STI treatment. Young, Heather // New Zealand Doctor;4/9/2008, p17 

    The article presents recommendations for general practitioners providing treatment to patients with sexually transmitted infections (STI). In chlamydia trachomatis, test of cure is not recommended unless treatment compliance is in doubt, symptoms persist or reinfection is likely. Intramuscular...

  • The Effects of a Single Cervical Inoculation of Chlamydia trachomatis on the Female Reproductive Tract of the Baboon (Papio anubis). Bell, Jason D.; Bergin, Ingrid L.; Harris, Lisa H.; Chai, Daniel; Mullei, Isaac; Mwenda, Jason; Dalton, Vanessa K.; Vahratian, Anjel; LeBar, William; Zochowski, Melissa K.; Kiulia, Nicholas; Aronoff, David M.; Patton, Dorothy L. // Journal of Infectious Diseases;11/1/2011, Vol. 204 Issue 9, p1305 

    Background. The baboon (Papio hamadryas anubis) can be transcervically instrumented, facilitating studies of intrauterine contraception and reproductive tract infection. We sought to determine if the baboon could become infected with a single cervical inoculation of Chlamydia trachomatis...

  • The Role of Reinfection and Partner Notification in the Efficacy of Chlamydia Screening Programs. Heijne, Janneke C. M.; Althaus, Christian L.; Herzog, Sereina A.; Kretzschmar, Mirjam; Low, Nicola // Journal of Infectious Diseases;2/1/2011, Vol. 203 Issue 3, p372 

    Repeated Chlamydia trachomatis infections after treatment are common. One reason is reinfection from untreated partners in ongoing sexual partnerships. Mathematical models that are used to predict the impact of screening on reducing chlamydia prevalence often do not incorporate reinfection and...

  • Improving the management of chlamydia in non-GUM settings. Zhou, Judith; Roberts, Jonathan; Davies, Jules; Longbone, Matthew; Dean, Gillian // Sexually Transmitted Infections;May2013, Vol. 89 Issue 3, p266 

    The article discusses an initiative aimed at improving management of patients with chlamydia from obstetrics and gynaecology (O&G). A bespoke information technology lab-link was developed allowing downloads of Chlamydia trachomatis results to genitourinary medicine (GUM) liaison health advisers...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics